retatrutide autoimmune disorders vs. Tirzepatide: What's The Difference? – Forbes Health Analysis of hundreds of thousands

Gallbladder and biliary disease Several meta-analyses have found that GLP-1 agonists carry a modest increase in the risk of gallbladder or biliary disease (such as gallstones and cholecystitis), especially at higher doses, over longer durations, and when used mainly for weight loss [3]

They also found that GLP-1 slowed gastric emptying and decreased hunger cues

Distribution : Once in systemic circulation, retatrutide is extensively bound to albumin through its C18 fatty diacid moiety

Patients should feel comfortable raising any concerns about emotional or sexual changes with their prescribing clinician.

They may be subject to additional screening

But I never had much time for weight loss medication